Rigel Pharmaceuticals (RIGL) Cash & Current Investments (2010 - 2026)

Rigel Pharmaceuticals' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $146.7 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 90.25% year-over-year to $146.7 million; the TTM figure through Mar 2026 stood at $146.7 million (up 90.25% YoY), while the FY2025 annual figure was $155.0 million, up 100.4% from the prior year.
• Cash & Current Investments was $146.7 million for Q1 2026 at Rigel Pharmaceuticals, down from $155.0 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $155.0 million in Q4 2025 to a low of $49.1 million in Q2 2024.
• Historically, Cash & Current Investments has averaged $84.7 million across 5 years, with a median of $77.1 million in 2025.
• Biggest YoY gain for Cash & Current Investments was 173.27% in 2022; the steepest drop was 53.42% in 2022.
• A 5-year view of Cash & Current Investments shows it stood at $58.2 million in 2022, then fell by 2.19% to $56.9 million in 2023, then surged by 35.81% to $77.3 million in 2024, then jumped by 100.4% to $155.0 million in 2025, then declined by 5.34% to $146.7 million in 2026.
• The last three Cash & Current Investments figures came in at $146.7 million (Q1 2026), $155.0 million (Q4 2025), and $137.1 million (Q3 2025), per Business Quant data.